Clinical Trials Sponsored by Pharmaceutical Product Development, LLC

Total 86 results

GE Healthcare
Pharmaceutical Product Development, LLC

Completed

An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

Coronary Artery Disease (CAD)

United States, Germany, Switzerland, Canada, Netherlands, France, Finland
Emergent Product Development Seattle LLC

Terminated

Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome

Mycosis Fungoides | Sezary Syndrome

United States, Spain, France, Germany, Italy
Pfizer
Emergent Product Development Seattle LLC

Completed

Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States
Pfizer
Emergent Product Development Seattle LLC

Completed

Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis

Arthritis, Rheumatoid

Japan
Pfizer
Emergent Product Development Seattle LLC

Completed

Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Canada
Pfizer
Emergent Product Development Seattle LLC

Completed

Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis

Active Rheumatoid Arthritis

United States, Canada, Serbia, Japan, Spain, Poland, Hungary, Argentina, Chile, Mexico
Sebela Pharmaceuticals Development LLC

Completed

Safety and Efficacy Study of an Edible Colonoscopy Preparation

Colon Prep for Colonoscopy

United States
ViiV Healthcare
GlaxoSmithKline; Pharmaceutical Product Development (PPD), Inc

Completed

To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers

HIV Infections

United States
SCRI Development Innovations, LLC
Novartis Pharmaceuticals

Completed

A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors

Metastatic or Unresectable Solid Tumor Malignancy

United States
SCRI Development Innovations, LLC
Aventis Pharmaceuticals

Completed

Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer

Breast Cancer
SCRI Development Innovations, LLC
Novartis Pharmaceuticals

Terminated

LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

Small Cell Lung Cancer | Ovarian Cancer

United States
SCRI Development Innovations, LLC
Novartis Pharmaceuticals

Completed

Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer

Prostate Cancer

United States
Janssen Research & Development, LLC
Janssen Pharmaceuticals

Completed

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Influenza A

United States, Germany, Bulgaria, Canada, Estonia, Latvia, Belgium, Puerto Rico
SCRI Development Innovations, LLC
Aventis Pharmaceuticals

Completed

Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer

Breast Cancer
SCRI Development Innovations, LLC
Aventis Pharmaceuticals

Completed

Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer

Prostate Cancer

United States
SCRI Development Innovations, LLC
Aventis Pharmaceuticals

Completed

Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients

Lung Cancer

United States
SCRI Development Innovations, LLC
Novartis Pharmaceuticals

Terminated

LBH589 in Refractory Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

United States
SCRI Development Innovations, LLC
Novartis Pharmaceuticals; OSI Pharmaceuticals

Completed

Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Cellegy Pharmaceuticals

Completed

Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis

Ichthyosis
FDA Office of Orphan Products Development
SciClone Pharmaceuticals

Completed

Phase I Randomized Study of CPX for the Treatment of Adult Patients With Mild Cystic Fibrosis

Cystic Fibrosis
Jazz Pharmaceuticals
FDA Office of Orphan Products Development

Completed

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

Severe Hepatic Veno-Occlusive Disease

United States, Canada
Janssen Pharmaceutical K.K.
Janssen Research & Development, LLC

Terminated

A Study of JNJ-64530440 in Healthy Japanese Male Participants

Healthy

Japan
SCRI Development Innovations, LLC
Millennium Pharmaceuticals, Inc.; Aventis Pharmaceuticals

Completed

Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer

Prostate Cancer
SCRI Development Innovations, LLC
GlaxoSmithKline; OSI Pharmaceuticals

Completed

Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

Non Small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
GlaxoSmithKline; Aventis Pharmaceuticals

Completed

Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer

Breast Cancer
SCRI Development Innovations, LLC
AstraZeneca; Aventis Pharmaceuticals

Completed

Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer

Head and Neck Cancer

United States
SCRI Development Innovations, LLC
Millennium Pharmaceuticals, Inc.

Completed

Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

Metastatic Breast Cancer

United States
SCRI Development Innovations, LLC
Millennium Pharmaceuticals, Inc.

Completed

Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma

Multiple Myeloma

United States
SCRI Development Innovations, LLC
Infinity Pharmaceuticals, Inc.

Completed

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | T-cell Lymphoma

United States
SCRI Development Innovations, LLC
Novartis; Aventis Pharmaceuticals

Completed

Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer

Breast Cancer

United States
SCRI Development Innovations, LLC
Bayer; OSI Pharmaceuticals

Completed

Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib

Non-Small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Millennium Pharmaceuticals, Inc.

Completed

Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma

Multiple Myeloma

United States
Aegerion Pharmaceuticals, Inc.
FDA Office of Orphan Products Development

Completed

A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)

Homozygous Familial Hypercholesterolemia

United States, Canada, Italy, South Africa
NeuroHealing Pharmaceuticals Inc.
FDA Office of Orphan Products Development

Suspended

Efficacy Study of NH001 in Vegetative State & Minimally Conscious State Following a Traumatic Brain Injury (NH001-2)

Brain Injury

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

Cancer | Anemia | Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

Cancer | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRIT

Rheumatoid Arthritis | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation

Neoplasms | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Anemia | Aged | Hemoglobins
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia

Anemia | Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.

Kidney Diseases | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy

Cancer | Anemia | Epoetin Alfa
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa

Anemia

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.

Cancer | Anemia | Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients

Anemia | HIV
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery

Stomach Neoplasms | Rectal Neoplasms
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Anemia | Aged | Hemoglobins
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

PROCRIT and Short-Term Outcomes in Orthopedic Surgery

Anemia | Surgery, Arthroscopy

Clinical Trials Sponsored by Pharmaceutical Product Development, LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations